SP

SPIMACO

Riyadh SAFounded 19863,500 employees
Private CappharmaPrivateOncologyInfectious Disease
Platform: Saudi Pharma
Market Cap
N/A
All Drugs
2
Clinical Trials
4
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
LiravorutinibSPI-5919Approved3Small MoleculeCD47TROP-2 ADCGAIPF
LisotuximabSPI-932Phase 11Small MoleculeMETCAR-T CD19PBCDravet
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)
2025-07-06
Liravorutinib AdCom
IPF
Past
2026-02-12
Liravorutinib Ph3 Readout
IPF
Past
2027-03-06
Liravorutinib Ph3 Readout
IPF
Ph3 Readout
2028-09-01
Lisotuximab Interim
PBC
Interim
2029-02-22
Liravorutinib Ph3 Readout
GA
Ph3 Readout